- Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus)
[作者：Feys, HB; Roodt, J; Vandeputte, N; Pareyn, I; Lamprecht, S; van Rensburg, WJ; Anderson, PJ; Budde, U; Louw, VJ; Badenhorst, PN; Deckmyn, H; Vanhoorelbeke, K,期刊：Blood, 页码：2005-2010 , 文章类型： Article，,卷期：2010年116-12]
- Thrombotic thrombocytopenic purpura (TTP) is the prototypical microangiopathy characterized by disseminated microthromboses, hemolytic anemia, and ultimately organ dysfunction. A link with deficiency of the von Willebran...
- Procoagulant platelets: are they necrotic?
[作者：Jackson, SP; Schoenwaelder, SM,期刊：Blood, 页码：2011-2018 , 文章类型： Article，,卷期：2010年116-12]
- Apoptosis and necrosis represent distinct cell death processes that regulate mammalian development, physiology and disease. Apoptosis characteristically leads to the silent destruction and removal of cells in the absence...
- Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
[作者：Bianchi, G; Kyle, RA; Colby, CL; Larson, DR; Kumar, S; Katzmann, JA; Dispenzieri, A; Therneau, TM; Cerhan, JR; Melton, LJ; Rajkumar, SV,期刊：Blood, 页码：2019-2025 , 文章类型： Article，,卷期：2010年116-12]
- Monoclonal gammopathy of undetermined significance (MGUS) is associated with a long-term risk of progression to multiple myeloma (MM) or related malignancy. To prevent serious myeloma-related complications, lifelong annu...
- Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
[作者：Halbsguth, TV; Nogova, L; Mueller, H; Sieniawski, M; Eichenauer, DA; Schober, T; Nisters-Backes, H; Borchmann, P; Diehl, V; Engert, A; Josting, A,期刊：Blood, 页码：2026-2032 , 文章类型： Article，,卷期：2010年116-12]
- For older patients with early unfavorable or advanced stage Hodgkin lymphoma (HL) the prognosis is much worse than for younger HL patients. We thus developed a new regimen, BACOPP (bleomycin, adriamycin, cyclophosphamide...
- Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma
[作者：Gabriel, IH; Sergeant, R; Szydlo, R; Apperley, JF; deLavallade, H; Alsuliman, A; Khoder, A; Marin, D; Kanfer, E; Cooper, N; Davis, J; MacDonald, D; Bua, M; Foroni, L; Giles, C; Milojkovic, D; Rahemtulla, A; Rezvani, K,期刊：Blood, 页码：2033-2039 , 文章类型： Article，,卷期：2010年116-12]
- Natural killer (NK) cells exert anti-myeloma cytotoxicity. The balance between inhibition and activation of NK-cells played by the inherited repertoire of killer immunoglobulin-like receptor (KIR) genes therefore may inf...
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
[作者：Coiffier, B; Thieblemont, C; Van Den Neste, E; Lepeu, G; Plantier, I; Castaigne, S; Lefort, S; Marit, G; Macro, M; Sebban, C; Belhadj, K; Bordessoule, D; Ferme, C; Tilly, H,期刊：Blood, 页码：2040-2045 , 文章类型： Article，,卷期：2010年116-12]
- We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse larg...
- Human FANCC is hypomorphic in murine Fancc-deficient cells
[作者：Hays, LE; Keeble, WW; Yates, JE; Rathbun, RK; Koretsky, T; Olson, SB; Sun, ZJ; Clapp, DW; Bagby, GC,期刊：Blood, 页码：2057-2060 , 文章类型： Article，,卷期：2010年116-12]
- Fancc suppresses cross-linker-induced genotoxicity, modulates growth-inhibitory cytokine responses, and modulates endotoxin responses. Although loss of the latter function is known to account for endotoxin-induced marrow...
- Thymic stromal lymphopoietin from trophoblasts induces dendritic cell-mediated regulatory T(H)2 bias in the decidua during early gestation in humans
[作者：Guo, PF; Du, MR; Wu, HX; Lin, Y; Jin, LP; Li, DJ,期刊：Blood, 页码：2061-2069 , 文章类型： Article，,卷期：2010年116-12]
- Thymic stromal lymphopoietins (TSLPs) play critical roles in dendritic cell-mediated immune responses. In this study, we found that human trophoblasts and decidual epithelial cells in maternal-fetal interface of early pl...
- First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
[作者：Ravandi, F; O'Brien, S; Thomas, D; Faderl, S; Jones, D; Garris, R; Dara, S; Jorgensen, J; Kebriaei, P; Champlin, R; Borthakur, G; Burger, J; Ferrajoli, A; Garcia-Manero, G; Wierda, W; Cortes, J; Kantarjian, H,期刊：Blood, 页码：2070-2077 , 文章类型： Article，,卷期：2010年116-12]
- The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in ...
- Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
[作者：Herman, SEM; Gordon, AL; Wagner, AJ; Heerema, NA; Zhao, WQ; Flynn, JM; Jones, J; Andritsos, L; Puri, KD; Lannutti, BJ; Giese, NA; Zhang, XL; Wei, L; Byrd, JC; Johnson, AJ,期刊：Blood, 页码：2078-2088 , 文章类型： Article，,卷期：2010年116-12]
- Targeted therapy with imatinib in chronic myeloid leukemia (CML) prompted a new treatment paradigm. Unlike CML, chronic lymphocytic leukemia (CLL) lacks an aberrant fusion protein kinase but instead displays increased ph...
- Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells
[作者：Tanaka, R; Squires, MS; Kimura, S; Yokota, A; Nagao, R; Yamauchi, T; Takeuchi, M; Yao, H; Reule, M; Smyth, T; Lyons, JF; Thompson, NT; Ashihara, E; Ottmann, OG; Maekawa, T,期刊：Blood, 页码：2089-2095 , 文章类型： Article，,卷期：2010年116-12]
- Despite promising clinical results from imatinib mesylate and second-generation ABL tyrosine kinase inhibitors (TKIs) for most BCR-ABL(+) leukemia, BCR-ABL harboring the mutation of threonine 315 to isoleucine (BCR-ABL/T...
|